Related Experiment Video
Updated: Sep 27, 2025
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid
Bilal Rah1, Rafiq A Rather1, Gh Rasool Bhat1
1Advanced Centre for Human Genetics, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, India.
Abstract:
JAK/STAT signaling pathway is one of the important regulatory signaling cascades for the myriad of cellular processes initiated by various types of ligands such as growth factors, hormones, and cytokines. The physiological processes regulated by JAK/STAT signaling are immune regulation, cell proliferation, cell survival, apoptosis and hematopoiesis of myeloid and non-myeloid cells. Dysregulation of JAK/STAT signaling is reported in various immunological disorders, hematological and other solid malignancies through various oncogenic activation mutations in receptors, downstream mediators, and associated transcriptional factors such as STATs. STATs typically have a dual role when explored in the context of cancer. While several members of the STAT family are involved in malignancies, however, a few members which include STAT3 and STAT5 are linked to tumor initiation and progression. Other STAT members such as STAT1 and STAT2 are pivotal for antitumor defense and maintenance of an effective and long-term immune response through evolutionarily conserved programs. The effects of JAK/STAT signaling and the persistent activation of STATs in tumor cell survival; proliferation and invasion have made the JAK/STAT pathway an ideal target for drug development and cancer therapy. Therefore, understanding the intricate JAK/STAT signaling in the pathogenesis of solid malignancies needs extensive research. A better understanding of the functionally redundant roles of JAKs and STATs may provide a rationale for improving existing cancer therapies which have deleterious effects on normal cells and to identifying novel targets for therapeutic intervention in solid malignancies.
Insights
The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway regulates crucial cellular processes. Dysregulation, particularly STAT3 and STAT5 activation, drives cancer, making it a key therapeutic target.
Area of Science:
- Molecular Biology
- Cellular Signaling
- Oncology
Background:
- The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway is a critical signaling cascade regulating cellular processes like immune response, proliferation, and survival.
- Dysregulation of JAK/STAT signaling, often due to mutations in receptors or transcription factors (STATs), is implicated in various cancers and immunological disorders.
- Specific STAT members (STAT3, STAT5) promote tumor initiation and progression, while others (STAT1, STAT2) are vital for anti-tumor immunity.
Purpose of the Study:
- To explore the dual role of STATs in cancer, distinguishing between oncogenic and tumor-suppressive functions.
- To highlight the significance of JAK/STAT pathway dysregulation in solid malignancies.
- To underscore the potential of targeting the JAK/STAT pathway for novel cancer therapies.
Main Methods:
- Review and analysis of existing literature on JAK/STAT signaling.
- Examination of the roles of different STAT family members in cancer pathogenesis.
- Investigation of the therapeutic implications of targeting JAK/STAT signaling in solid tumors.
Main Results:
- Persistent activation of STATs, particularly STAT3 and STAT5, contributes to tumor cell survival, proliferation, and invasion.
- STAT1 and STAT2 play crucial roles in anti-tumor defense and immune response maintenance.
- The JAK/STAT pathway's involvement in cancer pathogenesis presents it as a promising target for drug development.
Conclusions:
- Understanding the complex roles of JAK/STAT signaling in solid malignancies is essential for advancing cancer research.
- Targeting the JAK/STAT pathway could lead to improved cancer therapies with potentially fewer side effects on normal cells.
- Further research into the functionally redundant roles of JAKs and STATs may reveal novel therapeutic strategies for solid tumors.
More Related Videos
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
06:19Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches
Published on: June 16, 2023
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:20The JAK-STAT Signaling Pathway